Literature DB >> 34554332

Metal-organic framework modified by silver nanoparticles for SERS-based determination of sildenafil and pioglitazone hydrochloride.

Yanru Ding1, Yuqi Cheng1,2, Baoqin Hao1, Lin Zhu3, Nan Zhang1, Bing Zhao3, Yuan Tian4.   

Abstract

A versatile surface-enhanced Raman scattering (SERS) assay has been established that can realize rapid and sensitive determination of sildenafil (SIL) and pioglitazone hydrochloride (PIO) adulteration in healthcare products. Metal-organic frameworks-silver nanoparticles (MOFs-AgNPs) with SERS activity were successfully prepared via in situ synthesis AgNPs on the MOFs surface. By virtue of the adsorptivity of MOFs, the MOFs-AgNPs could effectively concentrate the drug molecules on the electromagnetic enhancement areas of AgNPs. Moreover, the MOFs-AgNPs substrate exhibited more sensitive SERS activity than classical AgNPs with linear range of 1.0 × 10-7-1.0 × 10-5 mol L-1 for SIL and 8.0 × 10-7-3.0 × 10-5 mol L-1 for PIO and limit of detection (LOD) of 4.8 × 10-8 mol L-1 for SIL and 1.4 × 10-7 mol L-1 for PIO. The designed method realized the determination of SIL and PIO in commercial tablets and healthcare products with recoveries of 93.8-108.0% and 93.0-104.0%, respectively, with relative standard deviation (RSD) of 2.7-4.1% and 2.2-4.2%, respectively. The present system displayed little interference effect on determination. This work provides a multifunctional route for the determination of other drugs via the SERS technology.
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Austria, part of Springer Nature.

Entities:  

Keywords:  Healthcare products; MOFs-AgNPs; Pioglitazone hydrochloride; Sildenafil; Surface-enhanced Raman scattering

Mesh:

Year:  2021        PMID: 34554332     DOI: 10.1007/s00604-021-05008-4

Source DB:  PubMed          Journal:  Mikrochim Acta        ISSN: 0026-3672            Impact factor:   5.833


  1 in total

1.  Simultaneous LC-MS analysis of plasma concentrations of sildenafil, tadalafil, bosentan, ambrisentan, and macitentan in patients with pulmonary arterial hypertension.

Authors:  S Tanaka; S Uchida; A Hakamata; S Miyakawa; K Odagiri; N Inui; H Watanabe; N Namiki
Journal:  Pharmazie       Date:  2020-06-01       Impact factor: 1.267

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.